CompletedNot Applicable

Diagnostic Performance of the Vesical Imaging-Reporting and Data System (VI-RADS) in Detecting Muscle-invasive Bladder Tumour (MIBC) in Clinical Practice: Comparison With Transurethral Resection of Bladder Cancer (TURB) and Evaluation of Diagnostic Accuracy According to Tumour Location

Italy20 participantsStarted 2022-10-15

Plain-language summary

VI-RADS was an observational, prospective, multicenter, no profit study. The aim of the study was to clarify the clinical validity of the Vesical Imaging-Reporting and Data System (VI-RADS) for the assessment of muscle invasion (MI) status in comparison with transurethral resection of bladder cancer (TURB) and to evaluate the diagnostic accuracy of the score according to the specific tumour location.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patients with suspected primary bladder cancer at cystoscopy Exclusion Criteria: * Impaired renal function * claustrophobia * allergy to paramagnetic contrast agent

What they're measuring

Sensitivity of Vescical Imaging-Reporting and Data System (VI-RADS) in predicting muscle-invasive bladder cancer after transurethral resection

Timeframe: up to 12 weeks

Trial details

NCT IDNCT06337591

SponsorIstituto Nazionale di Ricovero e Cura per Anziani

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-03-10

View on ClinicalTrials.gov More Bladder Cancer trials